[Antiplatelet thromboprophylaxis of arterial vascular diseases and organovascular ischemic diseases].
Antiplatelet therapy by acetylsalicylic acid (ASA, aspirin) provided pivotal advances in the prevention and treatment of organovascular (angiovascular, cardiovascular, cerebrovascular, extremitovascular, renovascular, genitovascular, mesenteriointestinokolonovascular, bronchopulmovascular, oculovascular, otovascular and other) arterial ischemic diseases. Currently available antiplatelet drugs have some limitations which might be overcomed by improved dosing regimens, use of combination of agents affecting different platelet functions and, in particular, by the new antiplatelet drugs (new arterial antithrombotics) with distinct pharmacodynamic properties offering new advantages, including faster onset of action, greater potency, and reversibility of effects.Key words: arteriothromboprophylaxis - arterial thrombosis - classic antiplatelet drugs - new antiplatelet agents - organovascular arterial diseases.
Peter
P
Gavorník
Andrej
A
Dukát
Ľudovít
Ľ
Gašpar
Eva
E
Gavorníková
Naďa
N
Hučková
Anna
A
Petrášová
Gabriela
G
Gubo
Iveta
I
Gašparová
Lujza
L
Sabolová
D001241:Aspirin / Q000627:therapeutic use*; D006801:Humans; D015539:Platelet Activation; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010979:Platelet Function Tests; D013927:Thrombosis / Q000517:prevention & control*; D014652:Vascular Diseases / Q000188:drug therapy / Q000517:prevention & control*
D010975:Platelet Aggregation Inhibitors; D001241:Aspirin